Use of quantitative SPECT/CT reconstruction in 99mTc-sestamibi imaging of patients with renal masses [0.03%]
定量SPECT/CT重建在99mTc- sestamibi肾占位病变显像中的应用研究
Krystyna M Jones,Lilja B Solnes,Steven P Rowe et al.
Krystyna M Jones et al.
Objective: Technetium-99m (99mTc)-sestamibi single-photon emission computed tomography/computed tomography (SPECT/CT) has previously been shown to allow for the accurate differentiation of benign renal oncocytomas and hyb...
Diagnostic value of 99mTc-ethambutol scintigraphy in tuberculosis: compared to microbiological and histopathological tests [0.03%]
99mTc-乙胺丁醇显像在结核病诊断中的价值：与微生物学和病理组织学检查比较
A H S Kartamihardja,Y Kurniawati,R Gunawan
A H S Kartamihardja
Objective: Tuberculosis (TB) still remains the world's endemic infection. TB affects the lungs and any part of the body other than the lung. The diagnosis of TB has not changed much over the decades. Ethambutol is one of ...
Comparative Study
Annals of nuclear medicine. 2018 Jan;32(1):60-68. DOI:10.1007/s12149-017-1220-1 2018
Molecular imaging in musculoskeletal infections with 99mTc-UBI 29-41 SPECT/CT [0.03%]
用99mTc-UBI 29-41 SPECT/CT分子影像进行骨髓炎的诊断
Mike Sathekge,Osvaldo Garcia-Perez,Diana Paez et al.
Mike Sathekge et al.
Objective: To determine the added value of CT over planar and SPECT-only imaging in the diagnosis of musculoskeletal infection using 99mTc-UBI 29-4. Mater...
Evaluation of sequential SPECT and CT for targeted radionuclide therapy dosimetry [0.03%]
顺序SPECT和CT在靶向核素治疗剂量学中的评价研究
Tiantian Li,Nien-Yun Wu,Na Song et al.
Tiantian Li et al.
Purpose: In targeted radionuclide therapy (TRT), a prior knowledge of the absorbed dose biodistribution is essential for pre-therapy treatment planning. Previously, we showed that non-rigid organ-by-organ registration in ...
Kazuhiro Kitajima,Yasuo Miyoshi,Toshiko Yamano et al.
Kazuhiro Kitajima et al.
Objective: To investigate the prognostic value of preoperative FDG-PET/CT and diffusion weighted imaging (DWI) in patients with breast cancer. Methods: ...
Low levels of PSMA expression limit the utility of 18F-DCFPyL PET/CT for imaging urothelial carcinoma [0.03%]
低PSMA表达水平限制了18F-DCFPyL PET/CT在尿路上皮癌成像中的应用效力
Scott P Campbell,Alexander S Baras,Mark W Ball et al.
Scott P Campbell et al.
Objective: To explore the clinical utility of PSMA-targeted 18F-DCFPyL PET/CT in patients with metastatic urothelial carcinoma. Methods: ...
Influence of region-of-interest determination on measurement of signal-to-noise ratio in liver on PET images [0.03%]
感兴趣区确定对肝PET图像信噪比测定的影响
Shinji Amakusa,Koki Matsuoka,Masayuki Kawano et al.
Shinji Amakusa et al.
Objective: On 18F-fluoro-2-deoxy-D-glucose (18F-FDG) positron emission tomography (PET), signal-to-noise ratio in the liver (SNRliver) is used as a metric to assess image quality. However, some regions-of-interest (ROIs) ...
Feasibility of combined risk stratification with coronary CT angiography and stress myocardial SPECT in patients with chronic coronary artery disease [0.03%]
冠脉CT造影联合负荷心肌灌注显像评估慢性冠心病患者危险程度的可行性研究
Tomonari Kiriyama,Yoshimitsu Fukushima,Hiromitsu Hayashi et al.
Tomonari Kiriyama et al.
Objective: To examine the additional prognostic value of coronary CT angiography (CTA) over myocardial perfusion imaging (MPI) in patients with suspected or known coronary artery disease. ...
Predictive and prognostic value of 18F-DOPA PET/CT in patients affected by recurrent medullary carcinoma of the thyroid [0.03%]
18F-DOPA PET/CT在复发性甲状腺髓样癌患者中的预测和预后价值
Federico Caobelli,Agostino Chiaravalloti,Laura Evangelista et al.
Federico Caobelli et al.
Introduction: Medullary thyroid carcinoma (MTC) is a malignancy accounting for about 5-8% of thyroid cancers. Serum calcitonin and carcinoembryonic antigen (CEA) levels are widely used to monitor disease progression. Howe...
Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients [0.03%]
镭-223治疗转移性去势抵抗性前列腺癌患者的延迟效应
Marie Øbro Fosbøl,Peter Meidahl Petersen,Gedske Daugaard et al.
Marie Øbro Fosbøl et al.
Background: Radium-223-dichloride (Ra-223) is an alpha-emitting, bone seeking radionuclide therapy approved for patients with metastatic castration-resistant prostate cancer (mCRPC). In the fall of 2014, a global temporar...